Bacillus coagulans (B. coagulans) is a type of probiotic (“good” bacteria). It isn’t naturally found in the body, but it produces lactic acid in the gut.

Because B. coagulans produces lactic acid, it’s often misclassified as lactobacillus. Some products containing B. coagulans are marketed as Lactobacillus sporogenes. Unlike lactobacillus, B. coagulans forms spores. Spores are important for telling B. coagulans apart from other lactic acid bacteria.

People take B. coagulans for constipation and irritable bowel syndrome (IBS). It is also used for diarrhea, gas, indigestion, and many other conditions, but there is no good scientific evidence to support these other uses.

Don’t confuse B. coagulans with other probiotics, or with fermented food products such as fermented milk, kefir, or yogurt. These are not the same.

Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.

The effectiveness ratings for BACILLUS COAGULANS are as follows:

Possibly effective for…

• Constipation. Taking B. coagulans by mouth seems to help relieve constipation.
• A long-term disorder of the large intestines that causes stomach pain (irritable bowel syndrome or IBS). Taking B. coagulans by mouth seems to help relieve symptoms of IBS.

There is interest in using B. coagulans for a number of other purposes, but there isn’t enough reliable information to say whether it might be helpful.

When taken by mouth: B. coagulans is possibly safe. It’s been used safely in doses of up to 6 billion colony-forming units (CFUs) daily for up to 3 months. Lower doses have been used safely for up to 1 year.

Special precautions & warnings:

Pregnancy and breast-feeding: There isn’t enough reliable information to know if B. coagulans is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: B. coagulans is possibly safe when taken by mouth by infants and children. It’s been used safely in infants in doses of up to 100 million CFUs daily for up to one year.

Moderate

Be cautious with this combination.

Antibiotic drugs

B. coagulans is a type of friendly bacteria. Antibiotics are used to reduce harmful bacteria in the body. Taking antibiotics along with B. coagulans can reduce the effects of B. coagulans. To avoid this interaction, take B. coagulans products at least 2 hours before or after antibiotics.

There are no known interactions with herbs and supplements.

There are no known interactions with foods.

B. coagulans has most often been used by adults in doses of 1-2 billion colony-forming units (CFUs) by mouth daily for 4-12 weeks. Speak with a healthcare provider to find out what dose might be best for a specific condition.

B. Coagulans, Bacillus Bacteria, Bacillus Probiotics, Bactéries Bacilles, Bactéries à Gram Positif Sporogènes, Bactérie Gram Positive en Forme de Bâtonnet, Gram Positive Spore-Forming Rod, L. Sporogenes, Lactobacillus Sporogenes, Lactobacillus Sporogènes, Probiotic, Probiotique, Spore-Forming Lactobacillus.

To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.

1. Velayati A, Kareem I, Sedaghat M, et al. Does symbiotic supplementation which contains Bacillus Coagulans Lactobacillus rhamnosus, Lactobacillus acidophilus and fructooligosaccharide has favourite effects in patients with type-2 diabetes? A randomised, double-blind, placebo-controlled trial. Arch Physiol Biochem. 2021 Jun 2:1-8. View abstract.
2. Anaya-Loyola MA, Enciso-Moreno JA, López-Ramos JE, et al. Bacillus coagulans GBI-30, 6068 decreases upper respiratory and gastrointestinal tract symptoms in healthy Mexican scholar-aged children by modulating immune-related proteins. Food Res Int. 2019;125:108567. View abstract.
3. Venkataraman R, Shenoy R, Ahire JJ, Neelamraju J, Madempudi RS. Effect of Bacillus coagulans Unique IS2 with Lactulose on Functional Constipation in Adults: a Double-Blind Placebo Controlled Study. Probiotics Antimicrob Proteins 2021. View abstract.
4. Kang S, Park MY, Brooks I, et al. Spore-forming Bacillus coagulans SNZ 1969 improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial. Food Res Int 2021;146:110428. View abstract.
5. Madempudi RS, Neelamraju J, Ahire JJ, Gupta SK, Shukla VK. Bacillus coagulans Unique IS2 in constipation: A double-blind, placebo-controlled study. Probiotics Antimicrob Proteins. 2020;12:335-342. View abstract.
6. Wauters L, Slaets H, De Paepe K, et al. Efficacy and safety of spore-forming probiotics in the treatment of functional dyspepsia: a pilot randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2021;6:784-792. View abstract.
7. Hoffman JR, Hoffman MW, Zelicha H, ET AL. The Effect of 2 Weeks of Inactivated Probiotic Bacillus coagulans on endocrine, inflammatory, and performance responses during self-defense training in soldiers. J Strength Cond Res. 2019;33:2330-2337. View abstract.
8. McFarland LV, Karakan T, Karatas A. Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. EClinicalMedicine. 2021;41:101154. View abstract.
9. Gupta AK, Maity C. Efficacy and safety of Bacillus coagulans LBSC in irritable bowel syndrome: A prospective, interventional, randomized, double-blind, placebo-controlled clinical study. Medicine (Baltimore). 2021;100:e23641. View abstract.
10. Zhang J, Guo J, Li D, et al. The efficacy and safety of Clostridium butyricum and Bacillus coagulans in Helicobacter pylori eradication treatment: An open-label, single-arm pilot study. Medicine (Baltimore). 2020;99:e22976. View abstract.
11. Kumar VV, Sudha KM, Bennur S, Dhanasekar KR. A prospective, randomized, open-label, placebo-controlled comparative study of Bacillus coagulans GBI-30,6086 with digestive enzymes in improving indigestion in geriatric population. J Family Med Prim Care. 2020;9:1108-1112. View abstract.
12. Chang CW, Chen MJ, Shih SC, et al. Bacillus coagulans (PROBACI) in treating constipation-dominant functional bowel disorders. Medicine (Baltimore). 2020;99:e20098. View abstract.
13. Soman RJ, Swamy MV. A prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of SNZ TriBac, a three-strain Bacillus probiotic blend for undiagnosed gastrointestinal discomfort. Int J Colorectal Dis. 2019;34:1971-1978. View abstract.
14. Abhari K, Saadati S, Yari Z, et al. The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. Clin Nutr ESPEN. 2020;39:53-60. View abstract.
15. Maity C, Gupta AK. A prospective, interventional, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Bacillus coagulans LBSC in the treatment of acute diarrhea with abdominal discomfort. Eur J Clin Pharmacol. 2019;75:21-31. View abstract.
16. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121:119-24. View abstract.
17. Yang OO, Kelesidis T, Cordova R, Khanlou H. Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial. AIDS Res Hum Retroviruses 2014;30:988-95. View abstract.
18. Dutta P, Mitra U, Dutta S, et al. Randomised controlled clinical trial of Lactobacillus sporogenes (Bacillus coagulans), used as a probiotic in clinical practice, on acute watery diarrhea in children. Trop Med Int Health 2011;16:555-61. View abstract.
19. Kalman DS, Schwartz HI, Alvarez P, et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009;9:85. View abstract.
20. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:655-9. View abstract.
21. Mandel DR, Eichas K, Holmes J. Bacillus coagulans: a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010;10:1. View abstract.
22. Sari FN, Dizdar EA, Oguz S, et al. Oral probiotics: Lactobacillus sporogenes for prevention of necrotizing enterocolitis in very low-birth weight infants: a randomized, controlled trial. Eur J Clin Nutr 2011;65:434-9. View abstract.
23. Riazi S, Wirawan RE, Badmaev V, Chikindas ML. Characterization of lactosporin, a novel antimicrobial protein produced by Bacillus coagulans ATCC 7050. J Appl Microbiol 2009;106:1370-7. View abstract.
24. Pande C, Kumar A, Sarin SK. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial. Eur J Gastroenterol Hepatol 2012;24:831-9. View abstract.
25. Majeed M, Nagabhushanam K, Natarajan S, et al. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant irritable bowel syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J 2016;15:21. View abstract.
26. Chandra RK. Effect of Lactobacillus on the incidence and severity of acute rotavirus diarrhea in infants. A prospective placebo-controlled double-blind study. Nutr Res 2002;22:65-9.
27. De Vecchi E, Drago L. Lactobacillus sporogenes or Bacillus coagulans: misidentification or mislabeling? Int J Probiotics Prebiotics 2006;1:3-10.
28. Jurenka JS. Bacillus coagulans: Monograph. Altern Med Rev 2012;17:76-81. View abstract.
29. Urgesi R, Casale C, Pistelli R, et al. A randomized double-blind placebo-controlled trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2014;18:1344-53. View abstract.
30. Khalighi AR, Khalighi MR, Behdani R, et al. Evaluating the efficacy of probiotic on treatment in patients with small intestinal bacterial overgrowth (SIBO)–a pilot study. Indian J Med Res. 2014 N ov;140:604-8. View abstract.
31. Czaczyk K, Tojanowska K, Mueller A. Antifungal activity of Bacillus coagulans against Fusarium sp. Acta Microbiol Pol 2002;51:275-83. View abstract.
32. Donskey CJ, Hoyen CK, Das SM, et al. Effect of oral Bacillus coagulans administration on the density of vancomycin-resistant enterococci in the stool of colonized mice. Lett Appl Microbiol 2001;33:84-8. View abstract.
33. Hyronimus B, Le Marrec C, Urdaci MC. Coagulin, a bacteriocin-like inhibitory subtances produced by Bacillus coagulans I4. J Appl Microbiol 1998;85:42-50. View abstract.
34. Probiotics for antibiotic-associated diarrhea. Pharmacist’s Letter / Prescriber’s Letter 2000;16:160103.
35. Duc LH, Hong HA, Barbosa TM, et al. Characterization of Bacillus probiotics available for human use. Appl Environ Microbiol 2004;70:2161-71. View abstract.
36. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl Environ Microbiol 1996;62:1958-63. View abstract.
37. McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993;6:251-64. View abstract.
38. Reid G, Bruce AW, Cook RL, et al. Effect on urogenital flora of antibiotic therapy for urinary tract infection. Scand J Infect Dis 1990;22:43-7. View abstract.

Show more references